SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently seeing high volatility and intense community debate following an unexpected endorsement from Donald Trump, which has sparked speculation about institutional support and potential government contracts. Traders remain sharply divided, with bulls pointing to the company's defense-sector entrenchment while bears, including noted short-sellers, warn that its current valuation is unsustainable compared to emerging AI competition.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is currently seeing intense retail and institutional interest as investors bet on its electro-optic polymer technology to solve data center bottlenecks in the AI infrastructure cycle. The community remains deeply divided, with bulls pointing to recent foundry integration partnerships and the potential for a major industry acquisition, while skeptics warn of pre-revenue risks and argue the current valuation is driven by speculative hype rather than fundamental milestones.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs is seeing heightened attention following strong earnings results that highlighted robust performance in equities trading and investment banking. Market participants are actively discussing the bank's ability to navigate current market volatility, while debates continue regarding the broader financial sector's valuation and the impact of geopolitical and macroeconomic pressures on bank capital quality.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing extreme volatility driven by a major follow-on order for its 800G optical transceivers and intensifying speculation surrounding its role in hyperscale data center infrastructure. While the community is actively debating the company's valuation and reliance on a single key customer, bulls point to a massive production pipeline and long-term capacity expansion as structural catalysts for growth.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is trending as investors express strong bullish sentiment ahead of key clinical trial milestones, including upcoming pancreatic cancer data and the finalization of U.S. recruitment for its skin cancer trial. The community is highlighting the company's clean balance sheet and recent analyst upgrades as evidence that the stock is significantly undervalued, with many users actively accumulating shares in anticipation of a potential breakout.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing extreme volatility and intense community debate as the token surges on rumors of high-profile integrations and its expansion into Web3 entertainment. While some traders are celebrating massive gains and pointing to upcoming global event partnerships as long-term catalysts, others remain deeply skeptical, frequently labeling the project a speculative pump-and-dump scheme.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma Inc. is trending following contract awards from the U.S. government for quantum materials and high-speed datacom, signaling a potential shift toward commercialization that has sparked intense debate among investors. The community is sharply divided, with bulls pointing to the company's proprietary III-V-on-silicon platform and low-float potential, while vocal criticsciting lack of foundry partnerships and limited revenueare actively challenging the company's valuation and long-term viability.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Ideaya Biosciences is trending following positive Phase 2/3 clinical trial results for its darovasertib combination therapy in metastatic uveal melanoma, which showed significant improvement in progression-free survival and led to an overnight surge in stock price. Investors are actively discussing the potential for accelerated FDA approval, institutional accumulation of shares, and the company's strong positioning as a clinical-stage oncology leader.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The VanEck Semiconductor ETF (SMH) is trending as traders debate whether it is currently in a resilient bull phase driven by AI capex demand or if it is a crowded, overextended bubble prone to a sharp mean reversion. While some market participants are aggressively positioning for a pullback, others are closely watching the sector's relative strength compared to lagging software stocks as a bellwether for broader market sentiment.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as investors digest detailed Phase 3 data for Axpaxli, with clinical presentations at the Macula Society and investor webcasts fueling intense speculation regarding a potential regulatory path or acquisition. While the community is debating the clinical nuances of the trial results, sentiment is buoyed by heavy institutional interest and the stock's recovery from recent volatility as participants position themselves ahead of further updates.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Hennion & Walsh Asset Management Inc. Makes New $1.74 Million Investment in Fulgent Genetics, Inc. $FLGT

Hennion & Walsh Asset Management Inc. acquired a new stake in Fulgent Genetics, Inc. (NASDAQ:FLGT - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 66,190 shares of the company's stock, valued at approximately...

JPMorgan Chase & Co. Increases Position in Fulgent Genetics, Inc. $FLGT

JPMorgan Chase & Co. lifted its holdings in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT - Free Report) by 767.0% in the third quarter, according to its most recent disclosure with the Securities...

Short Interest in Fulgent Genetics, Inc. (NASDAQ:FLGT) Rises By 38.7%

Fulgent Genetics, Inc. (NASDAQ:FLGT - Get Free Report) saw a large increase in short interest in March. As of March 13th, there was short interest totaling 2,135,898 shares, an increase of 38.7% from...

Fulgent Genetics, Inc. (NASDAQ:FLGT) Receives Consensus Rating of "Hold" from Brokerages

Fulgent Genetics, Inc. (NASDAQ:FLGT - Get Free Report) has been assigned a consensus recommendation of "Hold" from the five analysts that are covering the stock, Marketbeat Ratings reports. One...

FLGT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Fulgent Genetics Inc.

The law firm of Kirby McInerney LLP continues its investigation on behalf of Fulgent Genetics Inc. (Fulgent or the Company) (NASDAQ:FLGT) investors concerning the Companys and/or members of its...

FULGENT GENETICS INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

The law firm of Kirby McInerney LLP is investigating potential claims against Fulgent Genetics Inc. (Fulgent or the Company) (NASDAQ:FLGT). The investigation concerns whether the Company and/or...

Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx

Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced the completion...

Fulgent Genetics (NASDAQ:FLGT) Stock Price Crosses Below 50-Day Moving Average - Here's Why

Fulgent Genetics (NASDAQ:FLGT) Stock Price Passes Below 50-Day Moving Average - Should You Sell...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent...

Fulgent Genetics (NASDAQ:FLGT) Releases Quarterly Earnings Results, Beats Expectations By $0.14 EPS

Fulgent Genetics (NASDAQ:FLGT - Get Free Report) issued its earnings results on Friday. The company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by...

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded by Ming Hsieh on May 13, 2016 and is headquartered in El Monte, CA.

Current Price	$14.43
Prev Close	$15.02
Open	$15.02
Dividend Yield	0.00%
50-Day Moving Average	$18.80
Beta	0.75
Avg. Volume	867,577.36
PE Ratio	-7.34

52-Week High	$31.04
52-Week Low	$13.46
Market Capitalization	$450.66M
EPS (Annual)	-$1.97
Price to Book	0.40
Revenue Per Employee	$240,082.59

FLGT
Fulgent Genetics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FLGT News

FLGTFulgent Genetics Inc